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Introduction
Lung cancer is the leading cause of cancer deaths worldwide among both men and women, with 159,480 deaths estimated for 2013 in the United States (1). Brain metastases from lung are found in 20-50% of patients with non-small-cell lung cancer (NSCLC) and cause the patients a worse prognosis (2) . Lung cancer accounts for the majority of brain metastases. In contrast to metastases from other primary cancer sites such as breast cancer, colorectal cancer, and melanoma that can develop over one year after diagnosis, brain metastases from lung cancer can occur within months after or even at the time of diagnosis of the primary (3).
Once cancer cells intravasate from the primary site into the blood and before extravasation and colonization in the distant organ, the first step for cancer cells to complete the process of metastasis is their adhesion to vascular endothelial cells (4) . Several genes related to lung cancer metastatic to the brain that play a role in cancer cells' adhesion to brain endothelial cells include N-cadherin, integrin, and a disintegrin and metalloproteinase domain 9 (ADAM9) (5, 6) . ADAM9 belongs to the ADAM family of type I transmembrane proteins, which are involved in several biological processes, including neurogenesis, angiogenesis, and cell adhesion and migration (7) . The disintegrin domain of ADAM9 adheres to cells by binding to integrins (8) or heparin sulfate proteoglycans (9) , and the metalloproteinase domain functions in ectodomain shedding to release a variety of cell-surface proteins, including growth factors, cytokines, cell adhesion molecules, and receptors (10) .
Overexpression of ADAM9 has been consistently observed in pancreatic, breast, and prostate cancers (11) (12) (13) . Using an artificial overexpression system, investigators showed that ectopic expression of ADAM9 in lung cancer cells correlated with metastases to the brain through the regulation of integrin Į3 and ȕ1 (6) . To further understand the mechanisms by which ADAM9 promotes lung cancer metastatic to the brain in addition to ADAM9's role in cancer cells' adhesion to brain endothelial cells, we analyzed the differential gene expression between control cells and ADAM9 knockdown lung cancer cells metastatic to the brain and investigated the ADAM9-related pathways required for lung cancer metastasis to the brain. We also analyzed tissue samples from lung adenocarcinoma patients to investigate the clinical relevance of ADAM9.
Materials and Methods

Cell lines and animal model
Human lung adenocarcinoma cell lines CL1-0 (low invasiveness) and F4 (high invasiveness) from the same lung cancer origin (14) and F4-luc cells with stable expression of high levels of luciferase were established as previously described (15) . Experiments were carried out within 6 months of acquiring the cells from the established cell bank to ensure that cells maintained their ability to form lung cancer tumors in SCID mice. All cell lines were tested to be free of Mycoplasma and authenticated by short tandem repeat (STR) DNA typing (Genelabs Life science, Taipei, Taiwan) in November 2013. To generate cell lines of lung cancer metastatic to the brain, parental F4-luc cells (5x10 4 cells) were injected intracardially into 8-week-old SCID mice (n=5) (BioLASCO, Taiwan) and imaged weekly by IVIS (In Vivo Imaging System) Spectrum Imaging system (Xenogen, Hopkinton, MA, USA) for one month under SPF condition.
When brain metastases were detected by IVIS, the whole brain was dissected, minced, treated with collagenase type IA (0.2 mg/ml, Sigma) for 1 hr, and then washed and cultured in DME/F12 plus 10% FBS media to get clones of the lung cancer cells metastatic to the brain such as Bm2 and Bm7. Bm7 cells were injected intracardially into SCID mice again, and the same process was repeated to verify the cells' ability to metastasize to the brain. Bm7brm cells were obtained from the second cycle ( Fig. 1 A) . To avoid increasing the risk of genetic mutation during the prolonged period in which cells were generated, Bm7 cells were used as brainmetastatic cells in this study. All animal experiments were carried out under protocols approved by the Institutional Animal Care and Use Committee of China Medical University and Hospital.
Microarray processing and survival analyses
Three public microarray datasets were analyzed: two were downloaded from the Gene Expression Omnibus (16), including GSE8894 (61 patients in South Korea, two adenocarcinoma patients were excluded because age was unavailable) (17) and GSE11969 (90 patients in Japan) (18) , and the third dataset, composed entirely of lung adenocarcinoma patients, was obtained from the Shedden et al. study (469 patients in the United States) (19) . For our analysis, only lung adenocarcinoma patients from each of the datasets were examined. We expanded the number of patient for the survival curve analysis by combining the GSE8894 and GSE11969 datasets (referred to as Asia datasets). After retrieving the raw data, a quantile normalization method was performed for each dataset to remove the potential systematic biases. Survival analyses were performed based on the procedures in our previous studies (20, 21) . Briefly, for each gene, samples were divided into two groups according to the following criteria: (a) a high group, in which gene expression levels of the specific gene were higher than the median in all samples, and (b) a low group, in which gene expression levels of the specific gene were lower than the median in all samples. Kaplan-Meier survival curves were used to assess the differences between these two groups. Finally, a Cox hazard regression model was used to evaluate the quantitative risk of the gene expression grouping in patients with lung adenocarcinoma.
Immunohistochemistry Staining
The primary and metastatic specimens were obtained from the files of the Department of Pathology of China Medical University Hospital in compliance with protocols approved by the CMUH IRB (DMR99-IRB-131). Group I (n=18), primary lung tumor from patient with earlystage disease without relapse for more than 4 years; Group II (n=24), primary lung tumor from patients with early-stage disease that relapsed in 1-3 years; Group III (n=21), primary lung tumor from patients with late-stage disease metastatic to brain or bone at diagnosis; Group IV (n=21), paired lung tumor metastatic to brain or bone from patients in Group III. Asian lung cancer tissue array was purchased from US Biomax (LC1006, Rockville, MD). ADAM9, CDCP1, and tPA expression in clinical specimens from lung cancer patients were detected by immunohistochemical staining as previously described (15) . Briefly, goat anti-mouse ADAM9
antibody (AF949, Abcam) (13), goat anti-human CDCP1 antibody (AB1377, Abcam) and rabbit anti-human tPA (sc-5241, Santa Cruz Biotechnology) were used to perform IHC staining using horseradish peroxidase-conjugated avidin biotin complex (ABC) from the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA) and AEC chromogen (Vector Laboratories). The sections were counterstained with hematoxylin and mounted. All stainings were evaluated by experienced histologists.
Results
ADAM9 expression is associated with lung cancer metastasis to the brain
In a series of established human lung cancer cell sublines metastatic to the brain (see Author Manuscript Published OnlineFirst on July 24, 2014; DOI: 10.1158/0008-5472.CAN- was higher than ADAM9 expression in the low metastatic CL1-0 and high metastatic F4 cells ( Fig. 1A; right) . The Bm7 cells showed stronger metastatic ability in vitro and were more drug resistant than the F4-luc parental cells were ( Supplementary Fig. S1A and B), a finding consistent with clinical observations in lung cancer patients with brain metastases (22) .
Furthermore, Bm7 cells maintained the luciferase activity of the original F4-luc cells for establishing an animal model of lung cancer metastatic to the brain (Fig. S1C) .
We generated two Bm7 ADAM9 knockdown cell lines (shADAM9-C and shADAM9-E) by lentivirus expressing shRNAs targeting different regions of ADAM9. The expression of ADAM9 was more strongly inhibited in shADAM9-E than in shADAM9-C cells ( Fig. 1B; top ). Bm7 cells with ADAM9 knockdown (Bm7-shADAM9-C and -E) had a significantly weaker migration rate than shGFP control cells had ( Fig. 1B ; bottom) but had a similar proliferation rate to controls within 2 days (Supplementary Fig. S1D ). Results from the in vitro blood-brain-barrier assay indicated that there were more trans-migrated cells in Bm7 than in CL1-0 or F4 cells ( Supplementary Fig. S1E ) but the increase in trans-migrated cells was attenuated in Bm7 ADAM9 knockdown cells (Fig. 1C) . However, adhesion of control and ADAM9 knockdown Bm7 cells to human brain endothelial cells (HBMEC) was not altered (Fig. 1D ). While these data indicated that adhesion to HBMEC required more than ADAM9 alone, all lung cancer cells metastatic to the brain demonstrated stronger adhesion than parental F4-luc did, further validating that lung cancer cells metastatic to the brain have a high ability to adhere to brain endothelial cells.
To study the metastatic effect of ADAM9 in vivo, control and Bm7-shADAM9 cells were introduced by intracardiac injection into SCID mice and monitored for brain metastasis, as this approach has been previously established for a preclinical metastasis model for studying metastasis to brain or bone (23) . Twenty days after injection, mice that received Bm7-shADAM9 cells had lower ability of lung cancer cells to metastasize to brain and/or bone than did mice in the control (Bm7-shGFP) group, as indicated by the loss of luciferase signals under IVIS imaging. In the Bm7-shGFP group, all mice developed tumor metastasis to brain, bone and lung whereas metastasis developed in 80% and 25% of mice in the Bm7-shADAM9-C and Bm7-shADAM9-E groups, respectively (Fig. 1E) . Further histological examination of brain sections confirmed tumor formation in the brains of mice in the Bm7-shGFP group (Fig. 1F) . Taken together, these data indicate that cells with higher levels of ADAM9 are also more metastatic and that depletion of ADAM9 significantly reduces cancer metastasis.
ADAM9 enhances CDCP1 expression and activation
While ectopic expression of ADAM9 in lung cancer cells was reported to correlate with brain metastasis through upregulation of integrin Į3 and ȕ1 (6), Bm7-shADAM9 cells did not significantly suppress surface integrin ȕ1 compared with suppression in parental or control cells when we detected total, active, and inactive integrin ȕ1, except for CL1-0 cells, which have low integrin ȕ1 expression ( Supplementary Fig. S2 ). These findings support our previous results showing that Bm7-shADAM9 cells did not affect cell adhesion (Fig. 1D) . To investigate how ADAM9 affects lung cancer metastatic to the brain and to determine which genes are regulated by ADAM9 to promote metastasis, we analyzed differential gene transcription profile by comparing the control cells and ADAM9 knockdown cells in two cell sublines of lung cancer metastatic to brain, Bm2 and Bm7, as well as comparing Bm2 and Bm7 with parental F4-luc cells. Genes with more than two-fold change were considered as likely to be involved in the ADAM9-associated lung cancer metastatic to the brain. A total of 182 differentially-expressed Table S1 ) was used in hierarchical clustering analysis ( Fig. 2A) . Using the Ingenuity Pathway Analysis (IPA) network generation algorithm to determine highly interconnected pathways representing fundamental biological functions, we noticed that ADAM9 and CUB-domain-containing protein 1 (CDCP1) were shown in one interaction network involved in cellular movement (Fig. 2B) . The protein levels of ADAM9 and total CDCP1 (both full-length and cleavage) were increased in cells from low metastatic (CL1-0) to high metastatic cell lines (Fig. 2C) . Notably, the cleaved CDCP1 was higher in the brain metastatic cells (Bm7) than in the F4 cells. We observed similar results (higher cleaved CDCP1) in the brain metastatic cell subline MDA-MB-231-brm (24) than in the parental MDA-MB-231 breast cancer cell line (Fig. 2C ). To further determine whether the metalloproteinase activity of ADAM9 proteins affects the expression level of CDCP1, we treated lung cancer Bm7 cells with a broad-spectrum metalloproteinase inhibitor BB-94. ADAM9 expression was suppressed under BB-94 treatment (Fig. 2D ). In addition, the levels of full-length CDCP1 proteins were strongly decreased at 160 μM BB-94 treatment whereas the levels of cleaved CDCP1 were slightly decreased ( Fig. 2D ). CDCP1 expression was slightly decreased in A549 cells treated with BB-94 (Fig. 2E ). These results suggest that the metalloproteinase activity of ADAM9 mainly affects the expression of full-length CDCP1 but not of CDCP1 cleavage as the latter may be regulated by other factors.
CDCP1 is a transmembrane protein involved in cell-cell interaction and has been shown to function as a regulator of anoikis resistance (which bypasses apoptosis induced by anchoragedependent cells detaching from the surrounding extracellular matrix) in lung adenocarcinomas (25) . CDCP1 is overexpressed in leukemia, metastatic colon cancer, and breast cancer (26) . De full-length CDCP1 ranges from 130 to 140 kDa, which is larger than calculated size of 90 kDa due to extensive glycosylation and is cleaved by a serine protease, e.g., matriptase, plasmin, or trypsin (28, 29) , through an unclear mechanism to generate a 70-kDa C-terminal fragment.
Proteolysis of CDCP1 induces tyrosine phosphorylation of its C-terminal 70-kDa fragment and recruitment of Src and PKCδ to initiate signaling pathways (30) . In Bm7-shGFP cells, two forms of CDCP1 proteins were detected, and the levels of the cleaved form were lower in Bm7-shADAM9-E cells (Fig. 3B ). The levels of tyrosine-phosphorylated-CDCP1-interacting signaling molecules (phospho-Src and phospho-PKCį) were also decreased in Bm7-shADAM9-E cells but only slightly affected in Bm7-shADAM9-C cells; that difference was associated with ADAM9 expression (Fig. 3B ). To further determine whether ADAM9-enhanced CDCP1-interacting signaling molecules was due to the more stable cleaved CDCP1 rather than to the full-length CDCP1, the degradation rate of two forms of CDCP1 was determined. Under cycloheximide treatment to block protein neosynthesis, the levels of full-length CDCP1 decreased after 6 hours whereas the levels of cleaved CDCP1 remained high for 24 hours in control cells. The calculated degradation rate of full-length CDCP1 was 2.9% per hour whereas Author Manuscript Published OnlineFirst on July 24, 2014; DOI: 10.1158/0008-5472.CAN- almost no degradation of the cleaved form was observed, indicating that cleaved CDCP1 is more stable than the full-length form (Fig. 3C) . Thus, ADAM9 likely enhances the CDCP1 signaling as more cleaved CDCP1 is present in the control cells.
Both forms of CDCP1 were tyrosine phosphorylated, an event required to overcome anoikis (25) , and no difference between the phospho-CDCP1 signal and total CDCP1 proteins in control or shADAM9-E cells was observed, suggesting that both forms (full-length and cleavage) of CDCP1 are functionally active (Fig. 3D) . To determine whether suppression of CDCP1 cleavage and CDCP1-interacting signaling molecules in ADAM9 knockdown cells influences the function of CDCP1 in anoikis resistance, we performed a soft agar assay and found that ADAM9 knockdown cells formed lower number of colonies than did the parental or control cells (Fig.   3E ). In addition, the number of apoptotic cells was higher in the Bm7-shADAM9-E than in the control group in an anchorage-free culture condition ( Table S1 ), high tPA (PLAT) expression and low PAI-1 (plasminogen activator inhibitor 1, SERPINE1) expression were observed in cancer cells metastatic to the brain ( Fig. 2A) . We further investigated whether ADAM9-regulated CDCP1 cleavage requires tPA activation by examining both tPA and PAI-1 expression. Since the ADAM9 levels in Bm7-shADAM9-C and -E remained high in the pooled population, we selected the stable clones with low ADAM9 expression for further experiments. The reduced levels of ADAM9 level in ADAM9 knockdown cells substantially decreased expression of fulllength and cleaved CDCP1 (Fig. 4B ). In addition, the mRNA and protein levels were lower for tPA and higher for PAI-1 ADAM9 knockdown stable clones than in the control cells ( Fig. 4A and B). The catalytic activity of tPA for plasminogen to plasmin conversion was also suppressed in ADAM9 knockdown cells (Fig. 4C) .
To investigate whether the activity of tPA correlates with ADAM9-regulated CDCP1 cleavage, tPA and PAI-1 knockdown cells ( Supplementary Fig. S4B ) were used to investigate the correlation of CDCP1 cleavage with tPA activity. We measured the ratio of cleaved CDCP1 over the full-length CDCP1 and found that CDCP1 cleavage was attenuated in tPA knockdown but increased in PAI-1 knockdown cells compared with control cells (Supplementary Fig. S4C ). 
The activity of secreted tPA in the cultured media of these cells for plasminogen to plasmin conversion was measured ( Fig. 4C and Supplementary Fig. S4D ), and further analysis showed a high correlation between tPA activity and the ratio of CDCP1 cleavage to full-length CDCP1 (R = 0.89) among these cancer cells (Fig. 4D) . The percentage of apoptotic cells in an anchoragefree culture condition was increased in tPA knockdown cells over the percentage in the control cells ( Fig. 4E and Supplementary Fig. S3A ), which is consistent with our observation in ADAM9 and CDCP1 knockdown cells and indicates that tPA plays a role in anoikis resistance.
To test whether tPA addition could enhance CDCP1 cleavage, Bm7-shADAM9-E cells were treated with recombinant tPA proteins. In 10% serum culture media, cleaved CDCP1 was slightly increased at a higher dose of tPA treatment. Interestingly, CDCP1 cleavage in Bm7-shADAM9-E cells treated with 100 nM tPA was also enhanced to a level comparable with that in the control under serum-free conditions (Fig. 4F) ; this finding indicated that CDCP1 is likely a substrate of tPA.
Next, to investigate whether tPA directly cleaves CDCP1, full-length CDCP1 was isolated and treated with tPA and then analyzed by Western blotting. Plasmin and trypsin, which are known to cleave CDCP1, were included as the control. The conversion of full-length to cleaved CDCP1 was increased in a dose-dependent manner with tPA treatment similar to plasmin and trypsin treatment, indicating that tPA can directly cleave CDCP1, albeit at a high concentration (Fig. 4G) . These results suggest that tPA activation mediates ADAM9-enhanced CDCP1 cleavage.
Blocking the ADAM9-CDCP1-tPA axis in lung cancer cells prolongs animal survival time 
Next, we detected the migration rate of Bm7 cells by silencing genes at the ADAM9-CDCP1-tPA axis. We showed that control cells migrated farther and in a wider range of direction than Bm7-shADAM9, Bm7-shCDCP1, and Bm7-shtPA cells did, whereas Bm7-shPAI-1 rescued the migration ability ( Fig. 5A; top) . Quantitation of cellular movement confirmed that the loss of gene expression at ADAM9-CDCP1-tPA axis significantly inhibited cell migration ( Fig. 5A; bottom). These cells were further investigated for their metastatic ability in animal models by intracardiac injection in mice. Kaplan-Meier analysis indicated that mice inoculated with Bm7-shADAM9 and Bm7-shtPA cells had a significantly longer overall survival than did mice inoculated with the control cells. Notably, mice in the Bm7-shCDCP1 group had only moderately prolonged survival, but mice in the Bm7-shtPA group had the longest survival time (Fig. 5B) . When these cells were cultured in anchorage-free conditions, the sub-G1 percentage, which measures the apoptotic cell population, was higher in the Bm7-shtPA, moderately higher in the Bm7-shADAM9, and slightly higher in the Bm7-shCDCP1 cells than in the control cells in anchorage-free conditions (Fig. 5C) . These results provide a partial explanation for the longer survival time in the Bm7-shtPA group.
Next, we examined whether targeting the ADAM9-CDCP1-tPA axis could benefit lung cancer treatment using clinically available drugs such as dexamethasone and dasatinib.
Dexamethasone has been reported to inhibit CDCP1 cleavage through upregulation of PAI-1 (33) . Dasatinib is a dual Src/Abl kinase inhibitor that also targets several other kinases (34) with potent anti-proliferative activity against hematologic malignancies and cancer cell metastasis (35) . We found that dexamethasone enhanced PAI-1 expression in Bm7-shGFP cells and enhanced PAI-1 expression even more strongly in Bm7-shADAM9 cells and that dasatinib significantly inhibited the levels of pSFK and pPKCį in both cells (Fig. 5D) . Moreover, the two- (hazard ratios of 5.97 and 1.80, respectively; Fig. 6B ). To rule out statistical bias as the reason for these findings, we compared the predictability of ADAM9 versus CDCP1, and selected the more predictive of these two genes; the selected gene in random combination with one of other genes was then used to generate a profile that illustrates the predictability for the different pairs of genes. This gene predictability profile indicated that the predictor of ADAM9 plus CDCP1 ranked among the top 3.3% (GSE8894), 7.9% (GSE11969), and 18.6% (Shedden datasets) of random combination ( Figure 6C) . A number that is less than 20% indicated that our finding in prognosis analysis is not from statistical bias; thus, lung adenocarcinoma patients with
ADAM9
High /CDCP1 High expression indeed had a higher risk of mortality than those with expression in these specimens showed that the rate of positive ADAM9 detection increased almost two-fold in Groups II and III (54% and 52%) and reached a three-fold increase in Group IV (81%) compared with Group I (28%; Fig. 7C ). The rate of positive CDCP1 detection remained high in all four groups (from 67% to 71%) (Fig. 7C) . The rate of positive tPA detection increased from 22% to 81% (Fig. 7C) . The distribution of ADAM9 staining significantly correlated with the tPA staining results (p = 0.034, Fig. 7D ). On comparing the IHC staining scores in paired tumor specimens (primary and metastatic) from the same patient, the trend toward higher ADAM9 expression in metastatic tumor tissue was significantly increased only in patients with brain metastasis (p = 0.03) but not in patients with bone metastasis (p = 0.53, Fig.   7E ). The trend was absent in CDCP1 or tPA staining in patients with metastasis to brain or bone (Fig. 7E) . By setting the IHC score 1+ as positive staining, the triple-gene-positive (ADAM9-CDCP1-tPA positive staining) detection rate was low in patients without metastasis (Group I) but increased in patients with metastasis (Groups II and III) and even reached 50% in tumor specimens metastatic to brain or bone (Group IV; Fig. 7F ). In contrast, the triple-gene-negative (ADAM9-CDCP1-tPA negative staining) detection rate decreased from 22% in the nonmetastatic group to 5% in the metastatic groups and even to zero in patients with tumor metastatic to brain or bone. Taken together, these clinical results indicate that activation of the ADAM9-CDCP1-tPA axis contributes to lung cancer metastasis, especially to the brain. clinical evidence of ADAM9 expression in lung cancer is still lacking (6) . Our analysis of three lung cancer datasets and clinical samples suggested that ADAM9 alone is a good prognostic marker in the Asia datasets but not in the U.S. datasets. However, the combination of ADAM9 and CDCP1 appears to be a better prognostic marker for patient outcome, implying these genes play important roles in cancer metastasis. Such clinical evidence and results of our study do not indicate that ADAM9 is related specifically to metastases to the brain. Rather, they support that ADAM9 enhances the ability of cancer cells to establish distant metastases such as to the brain.
By investigating the paired clinical tumor specimens from the tumor's primary site and distant site, albeit in limited samples, we found that ADAM9 protein expression was significantly higher in lung tumor tissue metastatic to the brain than in the primary lung tumor but was not higher in lung tumor tissue metastatic to bone. While high levels of ADAM9 in cancer cells are essential for metastasis to the brain, these levels may not be specific to or only limited to the brain. In CAN-13-2995 addition, enhanced transmigration of the BBB by cancer cells appears to be a result of the enhanced expression of ADAM9 that triggers the activity of tPA.
The catalytic unit of tPA is known to function autonomously (37) , and there is no report showing ADAM9 cleaves tPA. While we did not provide sufficient evidence to demonstrate the role of ADAM9 protease activity in regulating the CDCP1-tPA axis, knocking down ADAM9 not only downregulated the transcription of tPA but also enhanced transcription of PAI-1, which suppressed the catalytic activity of tPA for plasminogen conversion to plasmin (Fig. 4C ). This suggests that ADAM9 indirectly regulates the tPA activity.
The mechanism by which ADAM9 increases the expression of CDCP1 is still unclear.
Heparin-binding EGF-like growth factor (HB-EGF), a member of EGF family, is overexpressed and associated with carcinogenesis in hepatoma and pancreatic cancer (38, 39) . The transmembrane domain of HB-EGF (pro-HB-EGF) can be cleaved by metalloproteases such as ADAM9, yielding a secreted form that activates EGFR (40) . Activation of EGFR signaling has been reported to upregulate CDCP1 mRNA and protein expression (41) . Interestingly, we also observed increased mRNA levels of HB-EGF in the brain-metastatic Bm7 cells compared with parental cells. Therefore, it is plausible that ADAM9 increases the expression of CDCP1 via ADAM9-dependent shedding of HB-EGF, leading to EGFR activation and subsequent upregulation of CDCP1 protein and mRNA expression. In addition, EGF has also been reported to increase tPA mRNA in HeLa cells (42) and enhance PAI-1 transcription via sequential activation of c-Src and PKCį in glioma cells (43) . However, we observed downregulation of tPA and upregulation of of PAI-1 in ADAM9 knockdown cells, suggesting other molecules besides EGF are involved in their regulation. PAI-1 transcription can be regulated by many transcription factors such as hypoxia-inducible factor-1Į (HIF-1Į) and early growth response protein 1 (EGR1). Although EGR1 is quickly activated under hypoxia, it can induce transcription and expression of PAI-1 independently of HIF-1α in murine macrophages (44) . From the transcriptome analysis (Supplementary Table S1 ), we notice that EGR1 mRNA levels were 10-fold higher in ADAM9 knockdown cells than in control cells, suggesting that ADAM9 may influence expression of PAI-1 through activation of EGR1, although more studies will be required to validate this.
The biological behavior and function of PAI-1 seems paradoxical. PAI-1 is thought to inhibit activation of tPA or uPA, an event that correlates with poor clinical outcomes in cancer (45, 46) ; however PAI-1 also serves as an indicator of poor prognosis in breast cancer (47) .
These findings may be attributed to differences in cell types and experimental models. Our data indicate that PAI-1 knockdown increases tPA activity, which results in more CDCP1 cleavage and cell migration ability, implying that PAI-1 inhibits lung cancer metastasis. More studies are warranted to clarify the role of PAI-1 in metastasis.
Here, our findings indicate that ADAM9 regulates a complicated network in lung cancer metastatic to the brain through tPA-mediated CDCP1 cleavage, especially in Asian patients, and establish a potentially important association for predicting or preventing cancer metastasis to the brain.
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